+

WO1997046585A3 - Fragments de leptine (proteine ob) - Google Patents

Fragments de leptine (proteine ob) Download PDF

Info

Publication number
WO1997046585A3
WO1997046585A3 PCT/EP1997/002968 EP9702968W WO9746585A3 WO 1997046585 A3 WO1997046585 A3 WO 1997046585A3 EP 9702968 W EP9702968 W EP 9702968W WO 9746585 A3 WO9746585 A3 WO 9746585A3
Authority
WO
WIPO (PCT)
Prior art keywords
leptin
compound
fragments
protein
analogue
Prior art date
Application number
PCT/EP1997/002968
Other languages
English (en)
Other versions
WO1997046585A2 (fr
Inventor
Kamal A Al-Barazanji
Jonathan Robert Sanders Arch
Patrick Camilleri
William Arthur Neville
Original Assignee
Smithkline Beecham Plc
Al Barazanji Kamal A
Jonathan Robert Sanders Arch
Patrick Camilleri
William Arthur Neville
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611775.9A external-priority patent/GB9611775D0/en
Priority claimed from GBGB9618540.0A external-priority patent/GB9618540D0/en
Priority claimed from GBGB9703493.8A external-priority patent/GB9703493D0/en
Priority to EP97929156A priority Critical patent/EP0912609A2/fr
Priority to JP10500240A priority patent/JP2000512137A/ja
Priority to HU0001774A priority patent/HUP0001774A3/hu
Application filed by Smithkline Beecham Plc, Al Barazanji Kamal A, Jonathan Robert Sanders Arch, Patrick Camilleri, William Arthur Neville filed Critical Smithkline Beecham Plc
Priority to IL12715397A priority patent/IL127153A0/xx
Priority to NZ332879A priority patent/NZ332879A/xx
Priority to CA002257240A priority patent/CA2257240A1/fr
Priority to BR9709529A priority patent/BR9709529A/pt
Priority to AU33372/97A priority patent/AU3337297A/en
Publication of WO1997046585A2 publication Critical patent/WO1997046585A2/fr
Publication of WO1997046585A3 publication Critical patent/WO1997046585A3/fr
Priority to NO985683A priority patent/NO985683D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une leptine, un peptide ob, ou un dérivé fonctionnel, un analogue ou un variant de ceux-ci, modulant le poids corporel essentiellement au moyen d'une modulation de l'utilisation de l'énergie. Elle concerne également une composition pharmaceutique contenant un tel composé, un procédé de préparation de celui-ci, ainsi que l'utilisation de ce composé en médecine.
PCT/EP1997/002968 1996-06-06 1997-06-04 Fragments de leptine (proteine ob) WO1997046585A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU33372/97A AU3337297A (en) 1996-06-06 1997-06-04 Fragments of leptin (ob protein)
BR9709529A BR9709529A (pt) 1996-06-06 1997-06-04 Fragmentos de leptina (proteína ob)
CA002257240A CA2257240A1 (fr) 1996-06-06 1997-06-04 Fragments de leptine (proteine ob)
JP10500240A JP2000512137A (ja) 1996-06-06 1997-06-04 レプチン（ｏｂタンパク質）のフラグメント
HU0001774A HUP0001774A3 (en) 1997-02-20 1997-06-04 Fragments of leptin (ob protein)
EP97929156A EP0912609A2 (fr) 1996-06-06 1997-06-04 Fragments de leptine (proteine ob)
IL12715397A IL127153A0 (en) 1996-06-06 1997-06-04 Fragments of leptin (ob protein)
NZ332879A NZ332879A (en) 1996-06-06 1997-06-04 Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes
NO985683A NO985683D0 (no) 1996-06-06 1998-12-04 Fragmenter av leptin (ob protein)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9611775.9A GB9611775D0 (en) 1996-06-06 1996-06-06 Novel compounds
GBGB9618540.0A GB9618540D0 (en) 1996-09-05 1996-09-05 Novel compounds
GB9618540.0 1997-02-20
GB9703493.8 1997-02-20
GBGB9703493.8A GB9703493D0 (en) 1997-02-20 1997-02-20 Novel compounds
GB9611775.9 1997-02-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09194866 A-371-Of-International 1998-12-04
US09/844,774 Continuation US20020037553A1 (en) 1996-06-06 2001-04-27 Fragments of leptin (ob protein)

Publications (2)

Publication Number Publication Date
WO1997046585A2 WO1997046585A2 (fr) 1997-12-11
WO1997046585A3 true WO1997046585A3 (fr) 1998-04-23

Family

ID=27268305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/002968 WO1997046585A2 (fr) 1996-06-06 1997-06-04 Fragments de leptine (proteine ob)

Country Status (15)

Country Link
EP (1) EP0912609A2 (fr)
JP (1) JP2000512137A (fr)
KR (1) KR20000016402A (fr)
CN (1) CN1221426A (fr)
AR (1) AR008765A1 (fr)
AU (1) AU3337297A (fr)
BR (1) BR9709529A (fr)
CA (1) CA2257240A1 (fr)
CZ (1) CZ397898A3 (fr)
IL (1) IL127153A0 (fr)
NO (1) NO985683D0 (fr)
NZ (1) NZ332879A (fr)
PL (1) PL330361A1 (fr)
TR (1) TR199802534T2 (fr)
WO (1) WO1997046585A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544492B1 (en) 1994-08-17 2009-06-09 The Rockefeller University OB polypeptides, modified forms and derivatives

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2335107C (fr) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Induction de genes a mediation par la leptine
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU782230B2 (en) 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
JP4756813B2 (ja) 2000-05-22 2011-08-24 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） レセプターを用いた相互作用の捕捉法
ES2350924T3 (es) 2001-10-22 2011-01-28 Amgen, Inc. Uso de leptina para el tratamiento de la lipoatrofia humana y método para determinar la predisposición a dicho tratamiento.
CA2535021A1 (fr) 2003-09-08 2005-03-17 Applied Research Systems Ars Holding N.V. Utilisation de l'insp035 dans le traitement de maladies fibreuses
AU2005211755B2 (en) 2004-02-11 2012-03-15 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP1812038A1 (fr) 2004-11-18 2007-08-01 VIB vzw Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine
WO2007022123A2 (fr) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Polypeptides hybrides presentant des proprietes selectionnables
NZ561361A (en) 2005-02-11 2010-02-26 Amylin Pharmaceuticals Inc GIP hybrid polypeptides with at least two hormonal activities
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
ES2319048B1 (es) * 2007-06-20 2010-02-10 Universitat De Les Illes Balears Uso de leptina en el tratamiento de alteraciones en los habitos alimentarios.
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
GB2451858A (en) * 2007-08-15 2009-02-18 Sergiy Konovchuk Methods of reducing body fat and treating obesity
AU2008333173A1 (en) 2007-12-05 2009-06-11 Astrazeneca Ab Piperazines as anti-obesity agents
EP2234992B1 (fr) 2007-12-05 2012-02-22 AstraZeneca AB Dérives de piperazine et leur utilisation en tant que modulateurs de récepteur de leptine
US20110275678A1 (en) * 2008-06-04 2011-11-10 Michael Higginbottom New Pyridine Derivatives as Leptin Receptor Modulator Mimetics
MX2010013355A (es) * 2008-06-04 2010-12-21 Astrazeneca Ab Nuevos compuestos v.
JP2012523434A (ja) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
US9475839B2 (en) * 2010-05-11 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
DK2621515T3 (en) 2010-09-28 2017-07-17 Aegerion Pharmaceuticals Inc Chimeric seal-human leptin polypeptide with increased solubility
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005309A2 (fr) * 1994-08-17 1996-02-22 The Rockefeller University Modulateurs de masse corporelle, proteines et acides nucleiques correspondants, et utilisations a des fins therapeutiques et diagnostiques
WO1996023519A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines agissant contre l'obesite
WO1996023514A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines anti-obesite
WO1996023815A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Anticorps contre les produits du gene ob
WO1996031526A1 (fr) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Agents antiobesite
WO1996034885A2 (fr) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Fragments peptidiques biologiquement actifs de proteines ob

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005309A2 (fr) * 1994-08-17 1996-02-22 The Rockefeller University Modulateurs de masse corporelle, proteines et acides nucleiques correspondants, et utilisations a des fins therapeutiques et diagnostiques
WO1996023519A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines agissant contre l'obesite
WO1996023514A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines anti-obesite
WO1996023815A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Anticorps contre les produits du gene ob
WO1996031526A1 (fr) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Agents antiobesite
WO1996034885A2 (fr) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Fragments peptidiques biologiquement actifs de proteines ob

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE TOXLIT AN 1970:3841 *
K.C. SAXENA ET AL.: "Hydrolysis of Peptides containing D-amino acids by Rabbit Tissues", INDIAN JOURNAL OF BIOCHEMISTRY, vol. 6, no. 4, 1969, pages 226 - 227 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544492B1 (en) 1994-08-17 2009-06-09 The Rockefeller University OB polypeptides, modified forms and derivatives

Also Published As

Publication number Publication date
WO1997046585A2 (fr) 1997-12-11
CA2257240A1 (fr) 1997-12-11
AU3337297A (en) 1998-01-05
PL330361A1 (en) 1999-05-10
AR008765A1 (es) 2000-02-23
TR199802534T2 (xx) 1999-03-22
KR20000016402A (ko) 2000-03-25
NZ332879A (en) 2000-09-29
BR9709529A (pt) 1999-08-10
CN1221426A (zh) 1999-06-30
CZ397898A3 (cs) 1999-04-14
EP0912609A2 (fr) 1999-05-06
NO985683L (no) 1998-12-04
IL127153A0 (en) 1999-09-22
NO985683D0 (no) 1998-12-04
JP2000512137A (ja) 2000-09-19

Similar Documents

Publication Publication Date Title
WO1997046585A3 (fr) Fragments de leptine (proteine ob)
WO1998007745A3 (fr) Compositions et methodes pour traitement des infections, utilisant des analogues d'indolicidine
HUP0001652A3 (en) Oxadiazole derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
EP1077217A3 (fr) Peptides neuroactives et leur utilisation
HUP9901874A3 (en) Human antibodies binding human tnfalfa, pharmaceutical compositions containing thereof and use thereof
AU1198699A (en) Novel heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
AU4552097A (en) 7alpha-(epsilon-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha-(epsilo-aminoalkyl)estratrienes and their use for preparing medicaments
AU6373094A (en) Enzyme-containing pharmaceutical or cosmetic composition, process for preparing the same and its use
AU5671594A (en) Human tissue factor related dna segments, polypeptides and antibodies
IL106600A (en) Peptides, pharmaceutical compositions containing the same and processes for the preparation thereof
AU1607497A (en) Novel aromatic piperazines derived from substituted cycloazanes, method for preparing same, pharmaceutical compositions, and use thereof as drugs
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU6362796A (en) Substituted 4-phenylaminothiazoles, their process for preparation and the pharmaceutical compositions containing them
AU2974189A (en) Pharmaceutical compositions containing lactams, new substituted lactams and processes for the preparation thereof
AU683787B2 (en) Aromatic heterocyclic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
AU5812800A (en) Pharmaceutical preparation
AU7201298A (en) Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
EP0783521B8 (fr) Composes polypeptides contenant d-2-alkyltryptophanne pouvant promouvoir la liberation de l'hormone de croissance
AU6858594A (en) Human influenza virus peptides binding hla-t molecule
EP1304118A3 (fr) Emplois thérapeutiques des produits de la protéine BPI
EP0770875A3 (fr) Marqueur et réactif pour diabète sucré et complication du diabète sucré
IL110954A0 (en) Pharmaceutical compositions comprising a retinoblastoma polypeptide or protein, and methods for the preparation and use thereof
EP1174439A3 (fr) Compositions et méthodes pour traitement des infections, utilisant des analogues d'indolicidine
AU688407B2 (en) Metal-bonding cystein-free peptides for diagnosis and therapy, process for producing them and pharmaceutical preparations containing these compounds
AU4865796A (en) Ophthalmic compositions including peptides and peptide derivatives and methods for using same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97195311.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 332879

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1998-3978

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2257240

Country of ref document: CA

Ref document number: 2257240

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998/02534

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/010406

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1997929156

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-3978

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1997929156

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997929156

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-3978

Country of ref document: CZ

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载